LFVN Lifevantage Corp
Pharmaceutical Preparations · Nasdaq · SEC CIK 849146 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY-24.8%
TTM net income YoY-73.1%
TTM EPS YoY-73.1%
Revenue 3-yr CAGR-6.9%
Net income 3-yr CAGR2.1%
Margins
Gross margin76.5%
Operating margin2.1%
Net margin1.6%
FCF margin5.1%
EBITDA margin3.8%
Returns
ROE8.2%
ROA4.5%
ROIC (approx.)14.0%
Asset turnover2.85x
Leverage & solvency
Liabilities / assets43.8%
Debt / equity0.00x
Current ratio1.91x
Interest coverage—
Cash quality & payout
Operating cash flow / net income4.81x
Accruals ratio-17.2%
Payout ratio88.2%
Capex / revenue2.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2027Q12026-09-30 | 2026Q4*2026-06-30 | 2026Q32026-03-31 | 2026Q22025-12-31 | 2026Q12025-09-30 | 2025Q4*2025-06-30 | 2025Q32025-03-31 | 2025Q22024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $37.12M | $42.38M | $43.72M | $48.93M | $47.56M | $55.11M | $58.44M | $67.76M |
| Cost of revenue | $9.15M | $9.33M | $9.17M | $12.72M | $9.74M | $11.06M | $11.11M | $13.20M |
| Gross profit | $27.97M | $33.04M | $34.54M | $36.21M | $37.82M | $44.05M | $47.33M | $54.57M |
| R&D expense | $200,000 | $200,000 | $200,000 | $200,000 | $300,000 | $400,000 | $400,000 | $200,000 |
| SG&A expense | $12.72M | $13.87M | $13.87M | $15.83M | $14.85M | $18.68M | $17.07M | $18.61M |
| Operating income | -$136,000 | $1.67M | $1.68M | $487,000 | $2.27M | $2.15M | $4.05M | $3.43M |
| Interest expense | $10,000 | — | — | — | $10,000 | — | — | — |
| Pretax income | -$184,000 | $1.70M | $1.66M | $473,000 | $2.24M | $2.40M | $4.18M | $3.09M |
| Income tax | $12,000 | $417,000 | $294,000 | $197,000 | $86,000 | $437,000 | $710,000 | $539,000 |
| Net income | -$196,000 | $1.28M | $1.36M | $276,000 | $2.15M | $1.96M | $3.47M | $2.55M |
| EBITDA | $594,000 | $2.36M | $2.39M | $1.24M | $2.88M | $2.90M | $4.86M | $4.23M |
| EPS (basic) | -0.02 | — | 0.11 | 0.02 | 0.17 | — | 0.28 | 0.21 |
| EPS (diluted) | -0.02 | — | 0.11 | 0.02 | 0.17 | — | 0.26 | 0.19 |
| Dividends declared per share | — | 0.05 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 |
| Weighted avg. shares (diluted) | 12.46M | — | 12.66M | 12.74M | 12.95M | — | 13.30M | 13.18M |
| Balance sheet | ||||||||
| Cash & equivalents | $13.73M | $14.92M | $12.48M | $10.18M | $13.09M | $20.20M | $22.47M | $21.59M |
| Receivables | $1.81M | $2.99M | $2.42M | $2.26M | $2.42M | $3.29M | $3.24M | $2.09M |
| Inventory | $14.23M | $16.17M | $18.38M | $18.98M | $20.59M | $20.67M | $22.22M | $17.47M |
| Current assets | $34.55M | $38.30M | $39.31M | $38.56M | $45.05M | $50.89M | $54.11M | $45.79M |
| PP&E, net | $8.06M | $7.31M | $6.85M | $6.43M | $6.00M | $6.21M | $6.73M | $7.14M |
| Goodwill | $465,000 | $465,000 | $472,000 | $472,000 | — | $0 | — | — |
| Intangibles | $2.93M | $3.06M | $3.19M | $3.32M | $245,000 | $245,000 | $224,000 | $257,000 |
| Total assets | $59.20M | $62.11M | $62.13M | $61.17M | $61.58M | $71.96M | $77.24M | $68.53M |
| Current liabilities | $18.09M | $20.23M | $20.10M | $19.01M | $18.83M | $27.22M | $32.58M | $27.55M |
| Total liabilities | $25.95M | $28.52M | $28.79M | $28.18M | $28.42M | $37.32M | $43.23M | $38.64M |
| Shareholders' equity | $33.26M | $33.59M | $33.34M | $32.99M | $33.16M | $34.64M | $34.01M | $29.89M |
| Shares outstanding | 12.59M | 12.52M | 12.61M | 12.79M | 12.69M | 12.43M | 12.58M | 12.55M |
| Cash flow statement | ||||||||
| Operating cash flow | $533,000 | $4.77M | $4.99M | $2.79M | -$2.31M | $1.03M | $2.23M | $9.20M |
| Capital expenditure | $1.24M | $1.04M | $1.01M | $1.08M | $439,000 | $199,000 | $331,000 | $492,000 |
| Free cash flow | -$707,000 | $3.73M | $3.98M | $1.71M | -$2.74M | $835,000 | $1.90M | $8.71M |
| Investing cash flow | -$1.24M | -$1.04M | -$1.01M | -$4.83M | -$439,000 | -$199,000 | -$331,000 | -$492,000 |
| Financing cash flow | -$603,000 | -$1.15M | -$1.60M | -$738,000 | -$4.30M | -$3.24M | -$1.13M | -$1.40M |
| Depreciation & amortization | $730,000 | $697,000 | $714,000 | $752,000 | $610,000 | $750,000 | $803,000 | $806,000 |
| Stock-based compensation | $306,000 | $263,000 | $700,000 | $600,000 | $826,000 | $1.54M | $1.50M | $1.70M |
| Dividends paid | $628,000 | $625,000 | $573,000 | $575,000 | $571,000 | $562,000 | $503,000 | $502,000 |
| Share buybacks | $0 | $460,000 | $1.01M | -$1,000 | $578,000 | $2.03M | $0 | $0 |
Free plan shows the latest 8 periods; Pro shows all 65 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.